{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.4","upperLimit":"99.2","value":"66.7"},{"groupId":"OG001","lowerLimit":"19.4","upperLimit":"99.4","value":"75.0"},{"groupId":"OG002","lowerLimit":"9.4","upperLimit":"99.2","value":"66.7"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"70.8","value":"0"},{"groupId":"OG004","lowerLimit":"16.7","upperLimit":"76.6","value":"45.5"},{"groupId":"OG005","lowerLimit":"5.3","upperLimit":"85.3","value":"40.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"description":"Disease control rate (DCR) is defined as the percentage of participants with a BOR of CR, PR, non-CR/non-PD or SD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 1 mg as a subcutaneous (SC) administration every 2 weeks (Q2W) for a maximum duration of 10.9 months.","id":"OG000","title":"PF-07209960 1 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 3 mg as a SC administration Q2W for a maximum duration of 5.1 months.","id":"OG001","title":"PF-07209960 3 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 10 mg as a SC administration Q2W for a maximum duration of 3.4 months.","id":"OG002","title":"PF-07209960 10 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 15 mg as a SC administration Q2W for a maximum duration of 5.8 months.","id":"OG003","title":"PF-07209960 15 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 20 mg as a SC administration Q2W for a maximum duration of 13.6 months.","id":"OG004","title":"PF-07209960 20 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 30 mg as a SC administration Q2W for a maximum duration of 12.6 months.","id":"OG005","title":"PF-07209960 30 mg SC"}],"paramType":"NUMBER","populationDescription":"Response evaluable set included all participants who received at least one dose of study treatment and had measurable disease at baseline and at least one post baseline disease assessment.","reportingStatus":"POSTED","timeFrame":"From start of the treatment until disease progression or death due to any cause, whichever occurred first (maximum up to 2 years approximately)","title":"Percentage of Participants With Disease Control Based on Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}